Á lódáil...
Opposing effects of acute versus chronic inhibition of p53 on decitabine’s efficacy in myeloid neoplasms
Decitabine is a DNA methyltransferase inhibitor and is considered a promising drug to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) with p53 mutations. However, whether loss of p53 in fact increases the response of MDS/AML cells to decitabine remains unclear. In this study,...
Na minha lista:
| Foilsithe in: | Sci Rep |
|---|---|
| Main Authors: | , , , , , , , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
Nature Publishing Group UK
2019
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6547685/ https://ncbi.nlm.nih.gov/pubmed/31160638 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-44496-6 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|